Catalysts for $AZN
71 tracked
Aug 22, 2024
approval
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Aug 15, 2024
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Jul 24, 2024
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Jun 14, 2024
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Jun 5, 2024
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Jun 5, 2024
approval
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Apr 22, 2024
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Feb 23, 2024
approval
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Jan 24, 2024
approval
KOSELUGO (SELUMETINIB SULFATE) — FDA approval
selumetinib sulfate
→
Dec 21, 2023
approval
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Dec 20, 2023
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Nov 16, 2023
approval
TRUQAP (CAPIVASERTIB) — FDA approval
capivasertib
→
Jul 17, 2023
approval
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Jun 16, 2023
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
May 26, 2023
approval
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Feb 1, 2023
approval
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Nov 10, 2022
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Oct 21, 2022
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Sep 2, 2022
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Aug 3, 2022
approval
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Aug 3, 2022
approval
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
May 11, 2022
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Mar 24, 2022
approval
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Dec 22, 2021
approval
KOSELUGO (SELUMETINIB SULFATE) — FDA approval
selumetinib sulfate
→
Dec 17, 2021
approval
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Jul 15, 2021
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Feb 19, 2021
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Nov 18, 2020
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Nov 18, 2020
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→
Nov 18, 2020
approval
IMFINZI (DURVALUMAB) — FDA approval
ASTRAZENECA PLC
→